Recommendation of Final Dividend for the Financial Year 2025-26
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emcure Pharmaceuticals reported strong FY2026 results with consolidated revenue of Rs. 92,035.40 million (up 16.6% YoY) and consolidated profit after tax of Rs. 9,412.69 million (up 33.1% YoY). The Board recommended a final dividend of Rs. 3.60 per equity share (36% payout on Rs. 10 face value), subject to shareholder approval at the ensuing AGM. Standalone profit more than doubled to Rs. 7,329.59 million from Rs. 3,171.28 million. The company also completed acquisitions including making Zuventus Healthcare a wholly-owned subsidiary and acquiring Cutimed Inc. through Mantra Pharma Inc. The auditors issued an unmodified opinion on the financial statements.
The robust profit growth and dividend recommendation signal financial strength, which could be positive for shareholder sentiment. The dividend payout ratio of 36% is moderate, indicating retained earnings for future growth investments.